2024-517360-37-00CompletedPhase 1
A study investigating the effect of different approved medications on how the body processes the study compound RO7795081. RO7795081 is a new compound that may potentially be used in the treatment of type 2 diabetes and weight control.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 18 Apr 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (actual)
- First submitted
- 23 Sept 2024
- Start date
- 22 Nov 2024
- Lead sponsor
- F. Hoffmann-La Roche AG
- Diseases
- Obesity, Type 2 diabetes
- EU CT number
- 2024-517360-37-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 50
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pharma Bio-Research Group | Groningen | Netherlands | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.